Pembimbing: dr. Norman Imansyah Rizal, Sp.

THT-KL
Karsinoma Nasofaring adalah tumor yang muncul dari
sel epitel yang menutupi permukaan dan batas
nasofaring
Sering terjadi pada orang yang tinggal di negara
berkembang terutama di Asia Tenggara. Penderita
biasanya memiliki kondisi sosial-ekonomi yang rendah
 Ca Nasofaring

Carrier EBV Makanan Jenis kelamin Genetik

Masalah pada satu sisi
telinga

Kongesti nasal persisten

Sekresi hidung yang

berdarah

Pembesaran nodi limfa

servikal (late stage)
Staging
Tumour Definition A B
Tx Primary tumour cannot be assessed
T0 no evidence of primary tumour
Tis carcinoma in situ
T1 tumour is confined to the nasopharynx

T2 extends to soft tissues of the without extension to the with extension to the
oropharynx and/or nasal fossa parapharyngeal region parapharyngeal
region

T3 invasion of adjacent bony structures and/or paranasal sinuses

T2: tumour extends to soft tissues

T4 Invasion
of of
theany one or more
oropharynx of the nasal
and/or following
•fossa
intracranial content
• cranial
T2a: nerves
without extension to the
• infratemporal fossa/masticator
parapharyngeal region space
• hypopharynx
T2b: with extension to the
• orbitparapharyngeal region
Nodular Definition A B

Nx nodes cannot be assessed

N0 no evidence of nodal involvement

N1 unilateral nodal involvement <6 cm maximal diameter above supraclavicular fossa

N2 bilateral nodal involvement <6 cm maximal diameter above supraclavicular fossa

N3 >6 cm maximal involvement of the

diameter (unilateral or supraclavicular fossa
bilateral)
Metastase Definition
Mx presence of metastases cannot be assessed
M0 no evidence of metastases
M1 distant metastases present
Stage Definition

Stage 0 Tis, N0, M0

Stage 1 T1, N0, M0

Stage 2a T2a, N0, M0

Stage 2b T2b, N0, M0 or T0-T2, N1, M0

Stage 3 T3, N0-2, M0 or T0-T2, N2, M0

Stage 4a T4, N0-2, M0

Stage 4b any T, N3, M0

Stage 4c any T, any N, M1

 Biopsi

Rhinoskopi Direk
Diagnosis Rhinoskopi Posterior

CT-Scan/MRI
Radioterapi

Kemoterapi

Operasi
• Evaluasi setiap 3 bulan di tahun pertama
• Evaluasi setiap 6 bulan di tahun kedua
• Evaluasi setiap 1 tahun di tahun ketiga
• 5 years survival rate hanya dengan radioterapi

• Stadium 1 (85%-95%)

• Stadium 2 (70%-80%)

• Stadium 3 & 4 (24%-80%)